Brokers Set Expectations for ZVRA Q4 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their Q4 2025 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff forecasts that the company will earn $0.04 per share for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other brokerages have also recently issued reports on ZVRA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Monday, September 30th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. JMP Securities assumed coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price on the stock. Finally, Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.62 on Thursday. The company has a fifty day moving average price of $8.03 and a two-hundred day moving average price of $6.49. Zevra Therapeutics has a one year low of $4.18 and a one year high of $9.21. The stock has a market cap of $453.57 million, a P/E ratio of -4.38 and a beta of 1.93. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the prior year, the business posted ($0.15) earnings per share.

Institutional Trading of Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in ZVRA. FMR LLC increased its holdings in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the period. Stonepine Capital Management LLC bought a new position in Zevra Therapeutics during the 3rd quarter worth $4,858,000. Vestal Point Capital LP acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $3,644,000. Propel Bio Management LLC bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at $1,248,000. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter worth $833,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.